Abstract |
Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin ( FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC). Here, we conducted a prospective confirmatory study to examine the predictive value of rs9679162 (located on GALNT14 gene) for the therapeutic responses using a split-dose FMP protocol. One hundred and seven advanced HCC patients receiving split-dose FMP therapy were enrolled. All patients were in Barcelona Clinical Liver Cancer Stage C with either main portal vein thrombosis and/or distant metastasis. Of them, 105 (98.1%) were Child-Pugh classification B. GALNT14 genotype was determined before therapy. Of the patients included, 28 were rs9679162 "TT" and 79 were "non-TT" ("GG" + "GT") genotype. The median overall survival, time-to-progression, response rate and disease control rate were ("TT" versus "non-TT") 6.8 versus 3.9 months (p < 0.001), 3.9 versus 2.1 months (p < 0.001), 28.6% versus 10.1% (p = 0.029) and 35.7% versus 15.2% (p = 0.030), respectively. Multivariate analysis indicated that rs9679162 genotype was an independent predictor for overall survival (p = 0.002). Categorical analysis showed that 17 patients with "TT" genotype, tumor size < 10 cm and neutrophils < 74% had a median overall survival of 25.5 months and a therapeutic response rate of 47.1%. In conclusion, this prospective study confirmed that GALN14 genotype (rs9679162) was an effective predictor for therapeutic outcome in advanced HCC patients treated by FMP chemotherapy. Combining GALNT14 genotype and clinical parameters, a subgroup of patients with excellent outcome was identified.
|
Authors | Chau-Ting Yeh, Kung-Hao Liang, Chen-Chun Lin, Ming-Ling Chang, Cheng-Lung Hsu, Chien-Fu Hung |
Journal | International journal of cancer
(Int J Cancer)
Vol. 134
Issue 5
Pg. 1214-24
(Mar 01 2014)
ISSN: 1097-0215 [Electronic] United States |
PMID | 23959947
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 UICC. |
Chemical References |
- Mitomycin
- N-Acetylgalactosaminyltransferases
- Cisplatin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy, genetics, mortality)
- Cisplatin
(therapeutic use)
- Female
- Fluorouracil
(therapeutic use)
- Genotype
- Humans
- Liver Neoplasms
(drug therapy, genetics, mortality)
- Male
- Middle Aged
- Mitomycin
(therapeutic use)
- N-Acetylgalactosaminyltransferases
(genetics)
- Neutropenia
(epidemiology)
- Polymorphism, Single Nucleotide
- Prospective Studies
|